# Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML

> **NCT07572695** · — · NOT_YET_RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 40 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Relapsed/Refractory Acute Myeloid Leukemia
- AML, Relapsed/Refractory

## Interventions

- **PROCEDURE:** Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT)
- **DRUG:** Post-transplant Maintenance Therapy

## Key facts

- **NCT ID:** NCT07572695
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2026-06
- **Final completion:** 2028-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07572695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07572695, "Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML". Retrieved via AI Analytics 2026-08-15 from https://api.ai-analytics.org/clinical/NCT07572695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*